STOCKS TELEGRAPH

Tag: BFRG Stock Price

  • Bullfrog AI (BFRG) Stock Surges On Revolutionary Findings

    Bullfrog AI (BFRG) Stock Surges On Revolutionary Findings

    The US stock market has witnessed a noteworthy upsurge in BullFrog AI Holdings, Inc. (NASDAQ: BFRG), with the company seeing an incredible 26.70% current-session spike to reach $3.345. This upsurge is credited to a ground-breaking partnership between BullFrog AI and the Lieber Institute for Brain Development (LIBD), which unveiled preliminary findings that might fundamentally alter the understanding and management of mental illnesses.

    BullFrog AI (BFRG) has officially unveiled the preliminary outcomes arising from its collaboration with LIBD, a partnership poised to reshape the landscape of psychiatric research. Employing BullFrog’s bfLEAP platform on LIBD’s extensive brain data has successfully stratified brain expression data, offering unparalleled insights into the intricate nature of psychiatric conditions.

    With BullFrog AI’s access to LIBD’s unmatched brain data, this partnership marks a turning point in the field of psychiatric research as it advances our understanding of the intricate biological underpinnings of mental illnesses. Not only do these results improve BFRG’s understanding of these illnesses, but they also pave the way for profitable strategic alliances with pharmaceutical firms that have the potential to provide significant profits.

    The exclusive LIBD data set includes gene expression information from an astounding 2,800 brain samples, including major depressive disorder, bipolar disorder, schizophrenia, and non-psychiatric control brains. Leveraging graph analytics, BullFrog AI and LIBD have achieved a groundbreaking feat by clustering subjects solely based on biological data, revealing distinct differences and similarities in biological pathways across various brain disorders.

    The market potential for new treatments in psychiatric disorders is vast and underserved. The collaboration between BullFrog AI and LIBD, with its innovative approach and promising early findings, presents a potential paradigm shift in treatment strategies. Identifying biological subtypes within disorders not only advances scientific understanding but also opens avenues for novel therapeutic approaches and personalized treatment strategies, addressing the increasing global demand for mental health solutions.

    This collaboration propels BullFrog AI to the forefront of psychiatric research, offering hope for more targeted and effective treatments. As the global demand for mental health solutions rises, this partnership not only demonstrates the potential for scientific advancement but also underscores the economic viability of BullFrog AI’s strategic engagements within the pharmaceutical industry.

  • What Is Hurting BullFrog AI (BFRG) Stock In Pre-Market Session Today?

    Bullfrog AI Holdings, Inc. (NASD: BFRG) witnessed a decline of -7.01% in its shares, trading at $4.64 during Wednesday’s premarket session.

    However, this setback followed a remarkable surge of 44.22% in the previous trading session, with Bullfrog stock closing at $4.99. The surge was attributed to the issuance of a significant US patent.

    In a recent announcement, BullFrog AI (BFRG) revealed that it would receive U.S. Patent No. 11,712,435 from the United States Patent and Trademark Office (USPTO) on August 1, 2023.

    This patent serves to protect the Company’s groundbreaking prodrugs derived from mebendazole and their application in treating various diseases, including cancer.

    These patented compounds showcase improved solubility and oral bioavailability compared to the original drug, resolving a major obstacle faced when evaluating mebendazole’s potential in oncology treatments.

    The grant of U.S. Patent No. 11,712,435 is a pivotal achievement for BullFrog AI, as it is the first patent resulting from the intellectual property licensed from Johns Hopkins University in October 2022.

    Under their exclusive worldwide, royalty-bearing license, BullFrog AI holds the rights to commercialize prodrugs of mebendazole that demonstrate enhanced solubility and bioavailability.

    This development significantly bolsters the protection of BullFrog AI’s meticulously curated and strategically acquired licensed product portfolio.

    With mebendazole showing promise in cancer treatment, these N-substituted prodrugs exhibit substantially improved solubility and bioavailability, heightening their therapeutic potential and increasing the probability of successful clinical outcomes.

    The company is eager to collaborate with strategic partners to capitalize on this valuable asset in treating glioblastoma and other oncology indications.

    Moreover, BullFrog AI expanded its worldwide license agreement with the Johns Hopkins Applied Physics Laboratory (APL) in Laurel, Maryland.

    This expansion enables the company to utilize patented technology to power its bfLEAP platform—an AI-driven system that analyzes drug development data, potentially expediting the availability of life-saving therapies and treatments for patients.

    The patented technology from APL utilized in bfLEAP incorporates advanced analytical models, capable of interpreting large, complex, and diverse datasets, even in the presence of incomplete and mixed numerical and categorical data.

    Notably, the technology offers explainable results and has demonstrated superior performance in benchmarking tests when detecting anomalies, patterns, and relationships, outperforming well-known algorithms.

    BullFrog (BFRG) AI’s recent achievements and strategic partnerships have positioned the company for further advancements in the field of drug development and oncology treatments, fostering hope for groundbreaking medical breakthroughs.